FMTM
MarketDesk Focused U.S. Momentum ETF
MarketDesk Focused U.S. Momentum ETF seeks to achieve long-term capital appreciation by investing primarily in U.S. equity securities that exhibit momentum characteristics.
US
EQUITY
Active
MANAGEMENT STYLE
$ 266.2 M
ASSETS UNDER MGMT
45 bp
EXPENSES
Fund Basics
| Inception date | Mar 19, 2025 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| CHARLES RIVER LABORATORIES | 3.9 % |
| PAYCOM SOFTWARE INC | 3.8 % |
| HALOZYME THERAPEUTICS INC | 3.7 % |
| SANCHEZ ENERGY CORP | 3.7 % |
| MARATHON PETROLEUM | 3.6 % |
| AMGEN INC | 3.6 % |
| CHIME FINANCIAL INC | 3.5 % |
| HF SINCLAIR CORPORATION | 3.4 % |
| RINGCENTRAL, INC. CLASS A | 3.4 % |
| PERKINELMER INC | 3.3 % |
Constituent Breakdown
| Number of holdings | 29 |
| Herfindahl-Hirschman Index | 343 |
| Wgt avg mkt cap (mns) | $85,907 |
| Large cap (>$10bn) | 88.6% |
| Mid cap ($2-10bn) | 3.4% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 97.0% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 92.0 % |
Historical Performance
Standardized Performance (as of 09/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 21.4% | 30.3% | -- | -- | -- | -- | -- | 33.1% |
| Dividend Yield | 0.0% | 0.4% | -- | -- | -- | -- | -- | 0.3% |
| Total Returns | 21.4% | 30.7% | -- | -- | -- | -- | -- | 33.3% | Ann. Volatility | 27.3% | 26.9% | -- | -- | -- | -- | -- | 24.4% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.58 | 58% |
| MSCI EAFE | 1.09 | 42% |
| MSCI Emg Mkts | 0.77 | 53% |
Liquidity Measures
| Avg. volume (000) | 165 |
| ADV traded (mns) | $6 |
| Turnover | 2.3% |
| Avg. Bid/Ask (% of price) | 0.04% |
Technical Indicators
| 30d moving avg. (EMA) | $39.37 |
| Relative strength (RSI) | 46 |
| MACD/Signal | -0.09/0.09 |
| Bollinger Bands (Upper/Lower) | $41.32/$37.89 |
| Short interest (% of AUM) | 1.1% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. FMTM |
Expenses vs. FMTM |
ALTAR Score™ vs. FMTM |
|---|---|---|---|---|
| SAMM | Strategas Macro Momentum ETF | 35.4% | +62 bp | +0.4% |
| FFTY | Innovator IBD 50 ETF | 27.5% | +58 bp | +1.4% |
| QMOM | Alpha Architect U.S. Quantitative Momentum ETF | 16.5% | -17 bp | +0.2% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 16.1% | +10 bp | -2.4% |
| SGRT | SMART Earnings Growth 30 ETF | 15.7% | +14 bp | -0.2% |
| COWG | Pacer US Large Cap Cash Cows Growth Leaders ETF | 15.4% | +4 bp | +0.2% |
| PDP | Invesco Dorsey Wright Momentum ETF | 15.4% | +17 bp | -0.6% |
| PBE | Invesco Biotechnology & Genome ETF | 15.3% | +14 bp | -4.7% |
| AIED | Defiance LLM Catalyst Momentum ETF | 15.1% | +30 bp | -0.8% |
| AGIQ | Sofi Agentic AI ETF | 14.8% | +24 bp | +1.0% |
Risk and Returns: FMTM vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/6/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
4.7%
ALTAR SCORE™
32nd
PERCENTILE
UNDERWEIGHT
ETFRC RATING
There are 1,388 funds in the US Equity category with an average
ALTAR Score™ of 5.7% and a standard deviation
of 2.1%. FMTM's ALTAR Score™ is approximately -0.5 standard
deviations above the category average. This places FMTM in the 32nd percentile
among funds in the category.
Sell-Side Consensus
$43.05
PRICE TARGET
+16.0%
UPSIDE